Andrew R Chapman1, Philip D Adamson1,2, Anoop S V Shah1, Atul Anand1, Fiona E Strachan1, Amy V Ferry1, Kuan Ken Lee1, Colin Berry3, Iain Findlay4, Anne Cruikshank5, Alan Reid5, Alasdair Gray6, Paul O Collinson7, Fred Apple8, David A McAllister9, Donogh Maguire10, Keith A A Fox1, Catalina A Vallejos11,12, Catriona Keerie13,14, Christopher J Weir13,14, David E Newby1, Nicholas L Mills1,14. 1. BHF Centre for Cardiovascular Science (A.R.C., P.D.A., A.S.V.S., A.A., F.E.S., A.V.F., K.K.L., K.A.A.F., D.E.N., N.L.M.), University of Edinburgh, United Kingdom. 2. Christchurch Heart Institute, University of Otago, New Zealand (P.D.A.). 3. Institute of Cardiovascular and Medical Sciences (C.B.), University of Glasgow, United Kingdom. 4. Department of Cardiology, Royal Alexandra Hospital, Paisley, United Kingdom (I.F.). 5. Department of Biochemistry, Queen Elizabeth University Hospital, Glasgow, United Kingdom (A.C., A.R.). 6. Emergency Medicine Research Group Edinburgh, Royal Infirmary of Edinburgh, United Kingdom (A.G.). 7. Departments of Clinical Blood Sciences and Cardiology, St George's, University Hospitals NHS Trust and St George's University of London, United Kingdom (P.O.C.). 8. Department of Laboratory Medicine and Pathology, Hennepin Healthcare/Hennepin County Medical Center & University of Minnesota, Minneapolis (F.A.). 9. Institute of Health and Wellbeing (D.A.McA.), University of Glasgow, United Kingdom. 10. Emergency Medicine Department, Glasgow Royal Infirmary, United Kingdom (D.M). 11. MRC Human Genetics Unit (C.A.V.), University of Edinburgh, United Kingdom. 12. The Alan Turing Institute, London, United Kingdom (C.A.V.). 13. Edinburgh Clinical Trials Unit (C.K., C.J.W.), University of Edinburgh, United Kingdom. 14. Usher Institute of Population Health Sciences and Informatics (C.K., C.J.W., N.L.M.), University of Edinburgh, United Kingdom.
Abstract
BACKGROUND: The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients with myocardial injury based on pathogenesis, but the clinical implications of implementing this guideline are not well understood. METHODS: In a stepped-wedge cluster randomized, controlled trial, we implemented a high-sensitivity cardiac troponin assay and the recommendations of the Universal Definition in 48 282 consecutive patients with suspected acute coronary syndrome. In a prespecified secondary analysis, we compared the primary outcome of myocardial infarction or cardiovascular death and secondary outcome of noncardiovascular death at 1 year across diagnostic categories. RESULTS: Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial injury by 36% (443/1233) and 43% (389/898), respectively. Compared with those without myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard ratio [HR] 5.64 [95% CI, 5.12-6.22]), but was similar across diagnostic categories, whereas noncardiovascular deaths were highest in those with acute myocardial injury (cause specific HR 2.65 [95% CI, 2.33-3.01]). Despite modest increases in antiplatelet therapy and coronary revascularization after implementation in patients with type 1 myocardial infarction, the primary outcome was unchanged (cause specific HR 1.00 [95% CI, 0.82-1.21]). Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to changes in investigation, treatment or outcomes. CONCLUSIONS: Implementation of high-sensitivity cardiac troponin assays and the recommendations of the Universal Definition of Myocardial Infarction identified patients at high-risk of cardiovascular and noncardiovascular events but was not associated with consistent increases in treatment or improved outcomes. Trials of secondary prevention are urgently required to determine whether this risk is modifiable in patients without type 1 myocardial infarction. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01852123.
BACKGROUND: The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients with myocardial injury based on pathogenesis, but the clinical implications of implementing this guideline are not well understood. METHODS: In a stepped-wedge cluster randomized, controlled trial, we implemented a high-sensitivity cardiac troponin assay and the recommendations of the Universal Definition in 48 282 consecutive patients with suspected acute coronary syndrome. In a prespecified secondary analysis, we compared the primary outcome of myocardial infarction or cardiovascular death and secondary outcome of noncardiovascular death at 1 year across diagnostic categories. RESULTS: Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial injury by 36% (443/1233) and 43% (389/898), respectively. Compared with those without myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard ratio [HR] 5.64 [95% CI, 5.12-6.22]), but was similar across diagnostic categories, whereas noncardiovascular deaths were highest in those with acute myocardial injury (cause specific HR 2.65 [95% CI, 2.33-3.01]). Despite modest increases in antiplatelet therapy and coronary revascularization after implementation in patients with type 1 myocardial infarction, the primary outcome was unchanged (cause specific HR 1.00 [95% CI, 0.82-1.21]). Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to changes in investigation, treatment or outcomes. CONCLUSIONS: Implementation of high-sensitivity cardiac troponin assays and the recommendations of the Universal Definition of Myocardial Infarction identified patients at high-risk of cardiovascular and noncardiovascular events but was not associated with consistent increases in treatment or improved outcomes. Trials of secondary prevention are urgently required to determine whether this risk is modifiable in patients without type 1 myocardial infarction. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01852123.
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard A Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michael Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Alan H B Wu; Robert H Christenson; Dina N Greene; Allan S Jaffe; Peter A Kavsak; Jordi Ordonez-Llanos; Fred S Apple Journal: Clin Chem Date: 2018-01-17 Impact factor: 8.327
Authors: Hanna K Gaggin; Yuyin Liu; Asya Lyass; Roland R J van Kimmenade; Shweta R Motiwala; Noreen P Kelly; Aditi Mallick; Parul U Gandhi; Nasrien E Ibrahim; Mandy L Simon; Anju Bhardwaj; Arianna M Belcher; Jamie E Harisiades; Joseph M Massaro; Ralph B D'Agostino; James L Januzzi Journal: Circulation Date: 2016-11-21 Impact factor: 29.690
Authors: Marc P Bonaca; Stephen D Wiviott; Eugene Braunwald; Sabina A Murphy; Christian T Ruff; Elliott M Antman; David A Morrow Journal: Circulation Date: 2011-12-23 Impact factor: 29.690
Authors: Kristina Lambrakis; John K French; Ian A Scott; Tom Briffa; David Brieger; Michael E Farkouh; Harvey White; Anthony Ming-Yu Chuang; Kathryn Tiver; Stephen Quinn; Billingsley Kaambwa; Matthew Horsfall; Erin Morton; Derek P Chew Journal: Am Heart J Date: 2018-10-25 Impact factor: 4.749
Authors: Thomas Nestelberger; Jasper Boeddinghaus; Patrick Badertscher; Raphael Twerenbold; Karin Wildi; Dominik Breitenbücher; Zaid Sabti; Christian Puelacher; Maria Rubini Giménez; Nikola Kozhuharov; Ivo Strebel; Lorraine Sazgary; Deborah Schneider; Janina Jann; Jeanne du Fay de Lavallaz; Òscar Miró; F Javier Martin-Sanchez; Beata Morawiec; Damian Kawecki; Piotr Muzyk; Dagmar I Keller; Nicolas Geigy; Stefan Osswald; Tobias Reichlin; Christian Mueller Journal: J Am Coll Cardiol Date: 2017-09-26 Impact factor: 24.094
Authors: Anoop S V Shah; David A McAllister; Rosamund Mills; Kuan Ken Lee; Antonia M D Churchhouse; Kathryn M Fleming; Elizabeth Layden; Atul Anand; Omar Fersia; Nikhil V Joshi; Simon Walker; Allan S Jaffe; Keith A A Fox; David E Newby; Nicholas L Mills Journal: Am J Med Date: 2014-11-28 Impact factor: 4.965
Authors: Andrew P DeFilippis; Andrew R Chapman; Nicholas L Mills; James A de Lemos; Armin Arbab-Zadeh; L Kristin Newby; David A Morrow Journal: Circulation Date: 2019-08-16 Impact factor: 29.690
Authors: Anoop S V Shah; Yader Sandoval; Ala Noaman; Anne Sexter; Amar Vaswani; Stephen W Smith; Mathew Gibbins; Megan Griffiths; Andrew R Chapman; Fiona E Strachan; Atul Anand; Martin A Denvir; Philip D Adamson; Michelle S D'Souza; Alasdair J Gray; David A McAllister; David E Newby; Fred S Apple; Nicholas L Mills Journal: BMJ Date: 2017-11-07
Authors: Matthew T H Lowry; Dimitrios Doudesis; Ryan Wereski; Dorien M Kimenai; Christopher Tuck; Amy V Ferry; Anda Bularga; Caelan Taggart; Kuan K Lee; Andrew R Chapman; Anoop S V Shah; David E Newby; Nicholas L Mills; Atul Anand Journal: Circulation Date: 2022-09-15 Impact factor: 39.918
Authors: Anda Bularga; Caelan Taggart; Filip Mendusic; Dorien M Kimenai; Ryan Wereski; Matthew T H Lowry; Kuan K Lee; Amy V Ferry; Stacey S Stewart; David A McAllister; Anoop S V Shah; Atul Anand; David E Newby; Nicholas L Mills; Andrew R Chapman Journal: JAMA Netw Open Date: 2022-07-01
Authors: Daniel E Forman; James A de Lemos; Leslee J Shaw; David B Reuben; Radmila Lyubarova; Eric D Peterson; John A Spertus; Susan Zieman; Marcel E Salive; Michael W Rich Journal: J Am Coll Cardiol Date: 2020-09-29 Impact factor: 24.094
Authors: Atul Anand; Kuan Ken Lee; Andrew R Chapman; Amy V Ferry; Phil D Adamson; Fiona E Strachan; Colin Berry; Iain Findlay; Anne Cruikshank; Alan Reid; Paul O Collinson; Fred S Apple; David A McAllister; Donogh Maguire; Keith A A Fox; David E Newby; Chris Tuck; Ronald Harkess; Catriona Keerie; Christopher J Weir; Richard A Parker; Alasdair Gray; Anoop S V Shah; Nicholas L Mills Journal: Circulation Date: 2021-03-23 Impact factor: 39.918
Authors: John Hung; Andreas Roos; Erik Kadesjö; David A McAllister; Dorien M Kimenai; Anoop S V Shah; Atul Anand; Fiona E Strachan; Keith A A Fox; Nicholas L Mills; Andrew R Chapman; Martin J Holzmann Journal: Eur Heart J Date: 2021-07-08 Impact factor: 35.855